As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.